Payment overview · 2025
General Payments
$594.77
42 reported records · 11 companies
Healthcare provider profile · identity verified
Douglas P Sieminski, DO
Allopathic & Osteopathic Physicians|Family Medicine · NEWTON, NJ · NPI 1922066125
Verified facts
What the public records show
CMS Open Payments records show Douglas P Sieminski, DO received $594.77 in general payments during 2025 across 42 reported records.
ABBVIE INC. accounted for 37.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $223.13 | 37.5% | 22 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $65.69 | 11.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $63.72 | 10.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.88 | 10.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.06 | 8.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.76 | 5.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.16 | 5.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.72 | 3.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.98 | 3.0% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $17.39 | 2.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.28 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $594.77 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $140.70 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $81.77 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $65.69 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $63.72 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $51.06 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.89 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.41 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.41 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.41 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.76 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.16 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 59 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 133 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 993 | 269 |
| Levothyroxine Sodium | Levothyroxine Sodium | 699 | 152 |
| Lisinopril | Lisinopril | 575 | 150 |
| Metformin Hcl | Metformin Hcl | 366 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 94 |
| Alprazolam | Alprazolam | 289 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 277 | 82 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 274 | 205 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 265 | 84 |
| Azithromycin | Azithromycin | 253 | 206 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 206 | 96 |
| Doxycycline Hyclate | Doxycycline Hyclate | 200 | 150 |
| Alendronate Sodium | Alendronate Sodium | 197 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 63 |
| Simvastatin | Simvastatin | 180 | 47 |
| Meloxicam | Meloxicam | 173 | 94 |
| Zolpidem Tartrate | Zolpidem Tartrate | 149 | 41 |
| Losartan Potassium | Losartan Potassium | 146 | 42 |
| Montelukast Sodium | Montelukast Sodium | 136 | 41 |
| Jardiance | Empagliflozin | 133 | 40 |
| Januvia | Sitagliptin Phosphate | 116 | 32 |
| Allopurinol | Allopurinol | 115 | 30 |
| Methylprednisolone | Methylprednisolone | 109 | 94 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 107 | 74 |
| Furosemide | Furosemide | 103 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 19 |
| Ezetimibe | Ezetimibe | 93 | 27 |
| Omeprazole | Omeprazole | 89 | 28 |
| Sertraline Hcl | Sertraline Hcl | 88 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 19 |
| Prednisone | Prednisone | 78 | 65 |
| Famotidine | Famotidine | 77 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 20 |
| Valsartan | Valsartan | 77 | 23 |
| Gabapentin | Gabapentin | 74 | 24 |
| Trazodone Hcl | Trazodone Hcl | 74 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 17 |
| Potassium Chloride | Potassium Chloride | 67 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 67 | 54 |
| Donepezil Hcl | Donepezil Hcl | 61 | 20 |
| Atenolol | Atenolol | 60 | 14 |
| Glipizide Er | Glipizide | 60 | 16 |
| Eliquis | Apixaban | 59 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 16 |
| Carvedilol | Carvedilol | 57 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 40 |
| Bupropion Xl | Bupropion Hcl | 45 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 45 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 41 | 12 |
| Finasteride | Finasteride | 41 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | 13 |
| Mometasone Furoate | Mometasone Furoate | 40 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 12 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 38 | 13 |
| Metformin Hcl Er | Metformin Hcl | 38 | 13 |
| Ramipril | Ramipril | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Lactulose | Lactulose | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Meclizine Hcl | Meclizine Hcl | 30 | 24 |
| Valacyclovir | Valacyclovir Hcl | 30 | 20 |
| Glipizide | Glipizide | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 25 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Naproxen | Naproxen | 23 | 12 |
| Cefdinir | Cefdinir | 21 | 21 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Colchicine | Colchicine | 17 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $594.77 · 42 records | ABBVIE INC. | ABRYSVO, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, INSPIRE, JARDIANCE, Korlym, NEFFY, NURTEC ODT, PREVNAR 20, QULIPTA, REXULTI, UBRELVY, VRAYLAR, Veozah, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error